RxDoctor Payments Data

Vivian Mapanao, MD

Family Medicine · Suffolk, VANPI 1629233242

Payments from drug & device makers

$2,511in general payments, 2019–2025

Across 163 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$700
  • AbbVie$561
  • GSK$360
  • AstraZeneca$227
  • Amgen$98
  • Boehringer Ingelheim$68
  • plus $498 from 16 others

What the payments were for

  • Food & beverage$2,505100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,511 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$198,856
Medicare patients
467
Services billed
3,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$194,051
EliquisApixaban88$114,240
JardianceEmpagliflozin85$102,898
TrulicityDulaglutide61$100,288
MounjaroTirzepatide64$67,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$54,005
JanuviaSitagliptin Phosphate51$49,512
RybelsusSemaglutide15$26,837
Janumet XrSitagliptin Phos/Metformin Hcl24$24,677
JanumetSitagliptin Phos/Metformin Hcl18$24,444
Tresiba Flextouch U-100Insulin Degludec11$24,198
TradjentaLinagliptin14$20,707
XareltoRivaroxaban20$18,650
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$14,857
LinzessLinaclotide11$13,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$700$220,889145 claims
Lilly USA, LLCTrulicity, Mounjaro$60$167,714125 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$68$129,621111 claims
PfizerEliquis$12$114,24088 claims
MerckJanuvia, Janumet Xr, Janumet$29$98,63493 claims
GSKTrelegy Ellipta$360$54,00549 claims
Johnson & JohnsonXarelto$42$18,65020 claims
AbbVieLinzess, Synthroid$561$15,62558 claims
Astellas Pharma US IncMyrbetriq$50$8,45412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →